A Retrospective Cohort Analysis of Analgosedation Requirements in COVID-19 Compared to Non-COVID-19 Extracorporeal Membrane Oxygenation Patients.

Publication date: Jan 01, 2025

Reports have described increased sedation requirements in patients with acute respiratory distress syndrome (ARDS) while on extracorporeal membrane oxygenation (ECMO) and for intubated COVID-19 patients. Thus, the objective of this study was to assess the analgosedation requirements of COVID-19 patients receiving ECMO compared to non-COVID-19 ECMO patients. This retrospective, observational cohort study included adult patients with ARDS requiring venovenous or venopulmonary arterial ECMO admitted to a single intensive care unit from January 2017 to December 2021. Patients were categorized as COVID-19 ECMO or non-COVID-19 ECMO. The primary outcome was median daily dosing of parenteral analgosedative medications. Pertinent secondary outcomes included incidence of extubation or tracheostomy and change in sedation following tracheostomy or addition of oral agents. A total of 109 patients were evaluated; 63 COVID-19 ECMO patients and 46 non-COVID ECMO patients. The primary outcome was statistically higher in the COVID-19 compared to non-COVID-19 patients for propofol (4131. 0 mg vs 2704. 8 mg, P 

Concepts Keywords
Daily Adult
December Aged
Parenteral analgesia
Tracheostomy Analgesics, Opioid
Analgesics, Opioid
ARDS
COVID-19
COVID-19
Dexmedetomidine
Dexmedetomidine
ECMO
Extracorporeal Membrane Oxygenation
Female
Humans
Hypnotics and Sedatives
Hypnotics and Sedatives
Intensive Care Units
Male
Middle Aged
Propofol
Propofol
Respiratory Distress Syndrome
Retrospective Studies
SARS-CoV-2
sedation
Tracheostomy

Semantics

Type Source Name
disease MESH COVID-19
disease MESH acute respiratory distress syndrome
drug DRUGBANK Propofol
drug DRUGBANK Dexmedetomidine

Original Article

(Visited 1 times, 1 visits today)